|
1. Biologie
|
|
|
|
Scientists pinpoint surprising origin of melanoma [VIB]
|
|
|
|
|
|
The
team was surprised to observe that these very aggressive tumors arise
from mature, pigment-producing cells called melanocytes. As melanoma
develops, these cells are eventually reprogrammed, lose their
differentiated features and become invasive, migratory cancer cells.
|
|
|
|
|
|
|
2. Etiologie
|
|
|
5 persistent myths about the causes of breast cancer [Cancer Research UK]
|
|
|
|
|
|
Essentially,
it’s very hard to prove a negative (which may be why the International
Agency for Research on Cancer (IARC) has only ever classified one
substance as probably not a cause of cancer in people). But the good
news is there’s no reason to be concerned about the deodorants, bras,
plastics and milk we encounter every day.
|
|
|
|
|
|
|
3.1 Prévention - Tabac
|
|
|
|
4.11 Dép., diag. & prono. - Ovaire
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
|
5. Traitements
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
|
5.2 Pharma
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
Pembrolizumab Secures FDA Approval in Stomach Cancer [NCI]
|
|
|
|
|
|
“Regrettably,
there are still many patients who don’t respond,” Dr. Fuchs continued.
The data suggest that there are “two opportunities” to change that. One,
he said, “is to look at [pembrolizumab] in earlier lines of therapy,
and the other is to figure out what [therapy] to partner with it to
augment that response.”
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
NICE expands Bayer's Stivarga prospects with move from CDF [FiercePharma]
|
|
|
|
|
|
How
did Bayer swing the move? First off, it submitted evidence showing
Stivarga can extend overall survival by more than 9 months compared with
best supportive care. And secondly, it served up a confidential
discount on the list price, which sits at £3,744 per three-week
treatment cycle, or just under £180 per patient per day.
|
|
|
|
|
|
|
NICE gives final draft guidance on two key cancer drugs [Pharmafile]
|
|
|
|
|
|
NICE
has announced it has published its final draft guidance for two cancer
treatments, covering Bayer’s Stivarga (regorafenib) in the treatment of
gastrointestinal stromal tumours (GIST), and Roche’s Erivedge
(vismodegib) in the treatment of advanced basal cell carcinoma (BCC)
that cannot be treated with surgery or radiotherapy.
|
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
6.11 Patients
|
|
|
|
Living With Cancer: Cancer Humor [NY Times]
|
|
|
|
|
|
In
Nina Riggs’s memoir “The Bright Hour,” she tells of commiserating with a
friend who is also dealing with triple negative breast cancer. They
imagine starting a business called Damaged Goods, which would sell a
line of morbid thank-you cards.
|
|
|
|
|
|